2026 ICD-10-CM Diagnosis Code T48.4X5SAdverse effect of expectorants, sequela

ICD-10-CM CodesS00–T88T36-T50T48

ICD-10-CM T48.4X5S
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T48.4X5S is a billable ICD-10-CM diagnosis code for adverse effect of expectorants, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.

Code Identity

ICD-10-CM Code
T48.4X5S
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of expectorants, sequela
Short Description
Adverse effect of expectorants, sequela
Same as the full description in the CMS dataset.
Parent Code
Adverse effect of expectorants

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT48Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system
This CodeT48.4X5SAdverse effect of expectorants, sequela

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T48.4X5S.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

T48.4X5S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acetylcysteine adverse reaction
  • Adverse reaction to bromhexine
  • Adverse reaction to expectorant
  • Beractant adverse reaction
  • Carbocisteine adverse reaction
  • Dornase alfa adverse reaction
  • Ipecacuanha adverse reaction
  • Liquorice adverse reaction
  • Mesna adverse reaction
  • Methylcysteine adverse reaction
  • Respiratory surfactant adverse reaction
  • Terpenes adverse reaction
  • Tyloxapol adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system (T48). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ075
Poisoning/toxic effect/adverse effects/underdosing, sequela
Default principal diagnosis: inpatient No · outpatient Yes

Clinical InformationClinical

  • Acetylcysteine

    the n-acetyl derivative of cysteine. it is used as a mucolytic agent to reduce the viscosity of mucous secretions. it has also been shown to have antiviral effects in patients with hiv due to inhibition of viral stimulation by reactive oxygen intermediates.
  • Ambroxol

    a metabolite of bromhexine that stimulates mucociliary action and clears the air passages in the respiratory tract. it is usually administered as the hydrochloride.
  • Bromhexine

    a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (from martindale, the extra pharmacopoeia, 30th ed, p744)
  • Glycyrrhizic Acid

    a widely used anti-inflammatory agent isolated from the licorice root. it is metabolized to glycyrrhetinic acid, which inhibits 11-beta-hydroxysteroid dehydrogenases and other enzymes involved in the metabolism of corticosteroids. therefore, glycyrrhizic acid, which is the main and sweet component of licorice, has been investigated for its ability to cause hypermineralocorticoidism with sodium retention and potassium loss, edema, increased blood pressure, as well as depression of the renin-angiotensin-aldosterone system.
  • Guaifenesin

    an expectorant that also has some muscle relaxing action. it is used in many cough preparations.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
AcetylcysteineT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
AmbroxolT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
BromhexineT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
CarbocisteineT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
S-Carboxymethyl-cysteineT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Cough mixture (syrup)T48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Cough mixture (syrup)::containing opiatesT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Cough mixture (syrup)::expectorantsT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Deglycyrrhizinized extract of licoriceT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
DomiodolT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
DornaseT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
EprazinoneT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Expectorant NECT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
GlycerylT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Glyceryl::gualacolateT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Glyceryl::nitrateT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Glyceryl::triacetate (topical)T48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Glyceryl::trinitrateT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Glycyrrhiza extractT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Glycyrrhizic acidT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Glycyrrhizinate potassiumT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Guaiacol derivativesT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
GuaifenesinT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
GuaimesalT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
GuaiphenesinT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Hydriodic acidT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
IpecacuanhaT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
LetosteineT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
LiquoriceT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Liquorice::extractT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
MecysteineT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
MesnaT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Mucolytic drugT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
MucomystT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
OrganidinT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Quillaja extractT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
RespaireT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Senega syrupT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
SobrerolT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Sputum viscosity-lowering drugT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
SteproninT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
SulfogaiacolT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
SuperinoneT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
TenoglicinT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
Terpin (cis) hydrateT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6
TyloxapolT48.4X1T48.4X2T48.4X3T48.4X4T48.4X5T48.4X6

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T48.4X5S to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
909.5 Lte efct advrs efct drug
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E945.5 Adv eff expectorants
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T48.4X5SOverview

Is T48.4X5S (Adverse effect of expectorants) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of expectorants, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character S in T48.4X5S mean?

The final character S makes this a sequela code: it reports a lingering problem that remains after the adverse effect of expectorants itself has resolved, not the original event.

What MS-DRG does T48.4X5S group to?

On inpatient claims, adverse effect of expectorants, sequela maps to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T48.4X5S be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of expectorants, sequela describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is T48.4X5S exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for adverse effect of expectorants, sequela on inpatient claims.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.